Skip to main content

Advertisement

SpringerLink
Log in

Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products

  • Research Article
  • Theme: Revisiting Drug Absorption and Elimination in the Design and Evaluation of Oral Modified Release Drug Products
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Physiologically based pharmacokinetic (PBPK) and absorption modeling approaches were employed for oral extended-release (ER) drug products based on an osmotic drug delivery system (osmotic pumps). The purpose was to systemically evaluate the in vivo relevance of in vitro dissolution for this type of formulation. As expected, in vitro dissolution appeared to be generally predictive of in vivo PK profiles, because of the unique feature of this delivery system that the in vitro and in vivo release of osmotic pump drug products is less susceptible to surrounding environment in the gastrointestinal (GI) tract such as pH, hydrodynamic, and food effects. The present study considered BCS (Biopharmaceutics Classification System) class 1, 2, and 3 drug products with half-lives ranging from 2 to greater than 24 h. In some cases, the colonic absorption models needed to be adjusted to account for absorption in the colon. C max (maximum plasma concentration) and AUCt (area under the concentration curve) of the studied drug products were sensitive to changes in colon permeability and segmental GI transit times in a drug product-dependent manner. While improvement of the methodology is still warranted for more precise prediction (e.g., colonic absorption and dynamic movement in the GI tract), the results from the present study further emphasized the advantage of using PBPK modeling in addressing product-specific questions arising from regulatory review and drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhang X, Lionberger RA. Modeling and simulation of biopharmaceutical performance. Clin Pharmacol Ther. 2014;95(5):480–2.

    Article  CAS  PubMed  Google Scholar 

  2. Zhang X, Lionberger RA, Davit BM, Yu LX. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 2011;13(1):59–71.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chow EC, Talattof A, Tsakalozou E, Fan J, Zhao L, Zhang X. Using physiologically based pharmacokinetic (PBPK) modeling to evaluate the impact of pharmaceutical excipients on oral drug absorption: sensitivity analyses. AAPS J. 2016.

  4. Lin HP, Sun D, Zhang X, Wen H. Physiologically based pharmacokinetic modeling for substitutability analysis of venlafaxine hydrochloride extended-release formulations using different release mechanisms: osmotic pump versus openable matrix. J Pharm Sci. 2016.

  5. Babiskin AH, Zhang X. Application of physiologically based absorption modeling for amphetamine salts drug products in generic drug evaluation. J Pharm Sci. 2015;104(9):3170–82.

    Article  CAS  PubMed  Google Scholar 

  6. Yu L, Zhang X, Lionberger R. Modeling and mechanistic approaches for oral absorption: quality by design in action. Ther Deliv. 2012;3(2):147–50.

    Article  CAS  PubMed  Google Scholar 

  7. Jiang W, Kim S, Zhang X, Lionberger RA, Davit BM, Conner DP, Yu LX. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm. 2011;418(2):151–60.

    Article  CAS  PubMed  Google Scholar 

  8. Lionberger RA, Raw AS, Kim SH, Zhang X, Yu LX. Use of partial AUC to demonstrate bioequivalence of zolpidem tartrate extended release formulations. Pharm Res. 2012;29(4):1110–20.

    Article  CAS  PubMed  Google Scholar 

  9. Bai JP, Hausman E, Lionberger R, Zhang X. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol Pharm. 2012;9(12):3495–505.

    Article  CAS  PubMed  Google Scholar 

  10. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22(10):1879–92.

    Article  CAS  PubMed  Google Scholar 

  11. Lee PI, and Li J-X. Evolution of oral controlled release dosage forms. In: Hong Wen KP, editor. Oral controlled release formulation design and drug delivery: theory to practice: John Wiley & Sons, Inc.; 2010. p. 1–20.

  12. Shamblin SL. Controlled release using bilayer osmotic tablet technology: reducing theory to practice. In: Hong Wen KP, editor. Oral controlled release formulation design and drug delivery: theory to practice: John Wiley & Sons, Inc; 2010. p. 129–153.

  13. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3(6):631–43.

    Article  CAS  PubMed  Google Scholar 

  14. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro in vivo correlation with permeability data from rats and humans. J Pharm Sci. 1996;85(10):1070–6.

    Article  CAS  PubMed  Google Scholar 

  15. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–85.

    Article  CAS  PubMed  Google Scholar 

  16. Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12(1):12–9.

    PubMed  PubMed Central  Google Scholar 

  17. Stevens RE, Limsakun T, Evans G, Mason Jr DH. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm Sci. 1998;87(12):1531–4.

    Article  CAS  PubMed  Google Scholar 

  18. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release. 2002;79(1–3):7–27.

    Article  CAS  PubMed  Google Scholar 

  19. Xu H, Li Z, Pan H, Zhang Z, Liu D, Tian B, Ma S, Song S, Pan W. A novel bi-layer ascending release osmotic pump tablet: in vitro investigation and in vivo investigation in pharmacokinetic study and IVIVC evaluation. Int J Pharm. 2013;458(1):181–7.

    Article  CAS  PubMed  Google Scholar 

  20. Tallapaka SH, Karuturi VK, Sotthivirat S, Vetro JA. Controlled Drug Delivery. In: Mitra AK, Kwarta D, Vadlapudi AD, editors. Drug Delivery. 1st edition. Burlington: Jones and Bartlet Learning; 2015. p. 108–28.

  21. Mansfield LE. Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis. Expert Opin Pharmacother. 2006;7(7):941–51.

    Article  CAS  PubMed  Google Scholar 

  22. Lukkari E, Taavitsainen P, Juhakoski A, Pelkonen O. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol Toxicol. 1998;82(4):161–6.

    Article  CAS  PubMed  Google Scholar 

  23. INVEGA Drug Label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916.

  24. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2009;48(9):585–600.

    Article  CAS  PubMed  Google Scholar 

  25. FDA. Clinical Pharmacology and Biopharmaceutics Review NDA-21999. 2016 11/02/2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021999s000_ClinPharmR_Part1.pdf.

  26. Stathopoulos E, Schlageter V, Meyrat B, Ribaupierre Y, Kucera P. Magnetic pill tracking: a novel non-invasive tool for investigation of human digestive motility. Neurogastroenterol Motil. 2005;17(1):148–54.

    Article  CAS  PubMed  Google Scholar 

  27. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27(8):886–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhang QY, Kaminsky LS, Dunbar D, Zhang J, Ding X. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine. Drug Metab Dispos. 2007;35(9):1617–23.

    Article  CAS  PubMed  Google Scholar 

  29. Howard DR, Haribhakti R, Kittner B, Agrawala P. Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.Curr Med Res Opin. 2005 May;21(5):769-76.

  30. Kaus LC, Gillespie WR, Hussain AS, Amidon GL. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm Res. 1999;16(2):272–80.

    Article  CAS  PubMed  Google Scholar 

  31. Kesisoglou F, Xia B, Agrawal NG. Comparison of deconvolution-based and absorption modeling IVIVC for extended release formulations of a BCS III drug development candidate. AAPS J. 2015;17(6):1492–500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Fairstein M, Swissa R, Dahan A. Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine. AAPS J. 2013;15(2):589–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Talattof A, Price JC, Amidon GL. Gastrointestinal motility variation and implications for plasma level variation: oral drug products. Mol Pharm. 2016;13(2):557–67.

    Article  CAS  PubMed  Google Scholar 

  34. Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, Gowland PA, Spiller RC, Amidon GE, Marciani L. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11(9):3039–47.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA

    Zhanglin Ni, Arjang Talattof, Jianghong Fan, Eleftheria Tsakalozou, Satish Sharan, Dajun Sun, Hong Wen, Liang Zhao & Xinyuan Zhang

  2. 10903 New Hampshire Ave., Bldg. 75, Room 4690, Silver Spring, Maryland, 20993, USA

    Xinyuan Zhang

Authors
  1. Zhanglin Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arjang Talattof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianghong Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eleftheria Tsakalozou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satish Sharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dajun Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hong Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xinyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinyuan Zhang.

Ethics declarations

Disclaimer

The views expressed in this article are those of the authors and not necessarily those of the Food and Drug Administration (FDA).

Additional information

Guest Editors: Duxin Sun and Simon Zhou

Electronic Supplementary Material

ESM 1

(DOCX 63 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ni, Z., Talattof, A., Fan, J. et al. Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products. AAPS J 19, 1045–1053 (2017). https://doi.org/10.1208/s12248-017-0075-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-017-0075-7

KEY WORDS

Search

Navigation